|
|
Volumn 49, Issue 5, 2002, Pages 425-428
|
|
Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients
a
a
a
a
a
b
a
a
a
a
a
a
a
|
|
Author keywords
Chinese; Gastric cancer; GL331; Refractory; Topoisomerase II
|
|
Indexed keywords
DNA TOPOISOMERASE (ATP HYDROLYSING);
GL 331;
GYRASE INHIBITOR;
ISOENZYME;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ARTICLE;
BLOOD TOXICITY;
BONE MARROW SUPPRESSION;
CANCER GROWTH;
CANCER PATIENT;
CANCER SURVIVAL;
CAUSE OF DEATH;
CHINESE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG METABOLISM;
DRUG SCREENING;
FEMALE;
HUMAN;
HUMAN TISSUE;
IMMUNOHISTOCHEMISTRY;
MALE;
NEUTROPENIA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
SEPSIS;
STOMACH CANCER;
TOXICITY;
ADULT;
AGED;
ANTIGENS, NEOPLASM;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
DNA TOPOISOMERASES, TYPE II, EUKARYOTIC;
DNA-BINDING PROTEINS;
ETOPOSIDE;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
IMMUNOHISTOCHEMISTRY;
MALE;
MIDDLE AGED;
STOMACH NEOPLASMS;
SURVIVAL ANALYSIS;
|
|
EID: 0036232644
PISSN: 03445704
EISSN: None
Source Type: Journal
DOI: 10.1007/s00280-002-0429-3 Document Type: Article |
|
Times cited : (14)
|
|
References (20)
|
